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ABSTRACT 
DISSOLUTION OF DISINTEGRATING SOLID DOSAGE FORMS IN A 
MODIFIED DISSOLUTION TESTING APPARATUS 2 
by 
Shrutiben Rameshbhai Parekh 
Dissolution tests are routinely carried out in the pharmaceutical industry to determine the 
dissolution rate of solid dosage forms. Dissolution testing serves as a surrogate for drug 
bioavailability through in vitro–in vivo correlation (IVIVR), and it additionally helps in 
guiding the development of new formulations and in assessing lot-to-lot consistency, thus 
ensuring product quality. The United States Pharmacopoeia (USP) Dissolution Testing 
Apparatus 2 is the device most commonly used for this purpose. Despite its widespread 
use, dissolution testing using this apparatus remains susceptible to significant error and 
test failures. There is documented evidence that this apparatus is sensitive to several 
geometric variables that can affect the release profile of oral dosage forms, including 
tablet location during the dissolution process. 
In this work, the dissolution profiles of disintegrating calibrator tablets containing 
Prednisone were experimentally determined using two systems, i.e., a Standard USP 
Dissolution Testing Apparatus 2 (Standard System) and a Modified Standard USP 
Dissolution Testing Apparatus 2 (Modified System) in which the impeller was located 8 
mm off the vessel centerline.  The dissolving tablets were located at different off-center 
positions on the vessel bottom to test the effect of tablet location in these two systems. 
Tablet dissolution in the Standard System was found to be strongly dependent on 
tablet location, as previously reported by this and other research groups.  This apparatus 
appears to generate variable results that may not be associated with the tablets 
undergoing testing but with the hydrodynamic characteristics of the apparatus itself and 
the location of the tablet on the vessel bottom.  However, when the same experiments 
were conducted in the Modified System, the dissolution profiles for the same tablets were 
found to be nearly completely insensitive to tablet location. 
The dissolution process in the Modified System was faster than that in the 
Standard System because of the improved mixing performance of the Modified System 
resulting from the non-symmetrical placement of the impeller.  However, when the 
Modified System was operated at 35 rpm, the dissolution profiles for centrally located 
tablets were found to be very similar to those for the Standard System operating at 50 
rpm.  Unlike the Standard System however, the dissolution profiles obtained at 35 rpm in 
the Modified System were found to be insensitive to tablet location. 
It can be concluded that the newly proposed Modified System for dissolution 
testing is a simple and yet robust and valid alternative to the current dissolution testing 
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Dissolution testing is widely used in pharmaceutical industry to determine the dissolution 
rate of solid dosage forms. Dissolution testing is one of the many tests that 
pharmaceutical companies must conduct on oral solid dosage forms, as required by the 
Food and Drug Administration (FDA) and specified in the United State Pharmacopoeia 
(USP). Dissolution testing serves as a surrogate for drug bioavailability through in vitro–
in vivo correlation, and it additionally helps in guiding the development of new 
formulations and in assessing lot-to-lot consistency, thus ensuring product quality.  Thus, 
dissolution testing is an essential requirement for the development and establishment of 
in vitro dissolution and in vivo performance (IVIVR), as well as for registration and 
quality control of different dosage forms. 
The United States Pharmacopoeia (USP) Dissolution Apparatus 2 is the device 
most commonly used for this purpose.  However, there is documented evidence that this 
apparatus is sensitive to several variables which affect the drug release profile of dosage 
forms. A number of studies have been published in literature to determine effects of 
tablet location, location of impeller, presence of baffles on drug release rate. In particular, 
previous work of the hydrodynamics of in vitro dissolution testing (Bai and Armenante, 
2009) has shown that tablet location can have a significant impact on drug dissolution 
rate in the USP Dissolution Apparatus 2.  Their results show that statistically significant 
differences exist in the dissolution profiles between centrally located tablets and tablets 






Despite recent findings, current dissolution testing practice remains susceptible to 
significant errors and test results.  Therefore, there is a need for the development of a 
more robust test possibly using a modification of the current USP Dissolution Apparatus 
2.  Thus, this project is aimed at filling this gap by investigating how the current USP 
Dissolution Apparatus 2 could be improved to yield a more robust testing device.   
To achieve this goal, a modified USP Dissolution Apparatus 2 was designed and 
assembled and the drug dissolution rates of disintegrating tablets (Prednisone 10mg) were 
obtained at different tablet locations at the bottom of the vessel.  In this Modified (USP) 
Dissolution Testing Apparatus 2 (Modified System) the impeller is located in an off-
center position which produces extensive changes in drug release profile due to change in 
the velocity profiles and shear rates.  Compared to the Standard USP Dissolution 
Apparatus 2, the modified apparatus produces much more consistent dissolution profiles.  
Therefore, it is proposed here that this Modified System be used for dissolution testing 
because of its simplicity and robustness, which could potentially make it a valid 
alternative to the current dissolution testing practice using the Standard USP Dissolution 









Solid dosage forms, such as tablets, are a convenient way of administering drugs to 
patients. Upon ingestion, tablets disintegrate into smaller fragments in the body 
compartment where absorption by the body is initiated, typically in the stomach or the 
upper intestine. These fragments dissolve in the digestive juices and can become 
absorbed by an epithelial layer such as the lining of the upper intestine. This complex in 
vivo process is routinely simulated in in vitro dissolution tests mandated by the food and 
drug administration (FDA) and specified in United States pharmacopoeia (USP). 
The USP (United States Pharmacopeia) Dissolution Apparatus 2 has been used in 
the pharmaceutical industry for decades, since this test was first was first was officially 
introduced almost 20 years ago (Cohen et al., 1990). Nevertheless, and despite its 
widespread use in the industry, dissolution testing remains susceptible to significant error 
and test failures. There have been numerous reports describing high variability of test 
results even when the calibrated tablets (i.e., tablets manufactured for the sole purpose of 
testing the proper operation of the dissolution test equipment) are used. The variability in 
dissolution rates is more pronounced in Apparatus 2 at the commonly used rotation speed 
of 50 rpm due to radial flow in the cylindrical USP vessel. Failures linked to dissolution 
testing resulted in 47 product recalls during the period 2000-2002, representing 16% of 
non-manufacturing recalls for oral solid dosage forms (FDC Reports, 2001, FDC Reports, 





of the equipment or deviation of dissolution profile from the standard caused by incorrect 
tablet formulation) failed dissolution tests can result in product recalls, costly 
investigations, potential production delays, which, in turn, can have a significantly 
negative financial impact. Therefore, the robustness and ruggedness of the test must be 
thoroughly evaluated during method development and validation. 
 
Figure 2.1 USP Dissolution Apparatus 2: typical commercial dissolution testing system 
containing several Apparatus 2 units. 
 
Some of the same studies have indicated that the hydrodynamics of the USP 
Apparatus 2 appears to play a major role in the poor reproducibility of dissolution testing 
data and the inconsistency of dissolution results. This is hardly surprising considering 
that the USP Dissolution Apparatus 2 is a small, unbaffled vessel with a hemispherical 
bottom provided with a slowly rotating paddle, in which a tablet (or another dosage form) 





resulting in fluid velocities whose directions and intensities are highly dependent on the 
location within the vessel (Bai et al., 2006). A pharmaceutical and analytical department 
of Novartis Pharmaceutical Corporation had also evaluated hydrodynamics of dissolution 
in USP Peak 
TM
 and flat bottom vessels using different solubility tablets and resulted in 
higher dissolution rates for Prednisone calibrator tablets indicating the presence of 
minimal flow or „dead zone‟ at the bottom of the vessel underneath the paddle.   
A literature review shows that numerous investigators have conducted 
hydrodynamic studies. Bocanegra et al. (1990) measured the flow field by Laser Doppler 
Anemometry, the first experimental measurement of this kind in dissolution vessels. 
More recently, Kukura et al. (2003) obtained experimental flow patterns using Particle 
Image Velocimetry (PIV) and Laser-Induced Fluorescence (LIF), and computed the 
velocity flow field using Computational Fluid Dynamics (CFD). Other researchers also 
made an effort to determine the flow field inside the USP Apparatus 2 vessel through 
CFD. Kukura et al. (2004) and Baxter et al. (2005) predicted the flow pattern and shear 
effects with CFD. Only a few researchers (Kukura et al. 2004, Baxter et al. 2005) have 
conducted dissolution test in which drug tablets were fixed at different locations along 
the bottom of the USP Dissolution Apparatus 2. More recently, Bai et al. (2007a, 2007b, 
2011) and Bai and Armenante (2008, 2009) have quantified the flow field in the USP 
Apparatus 2 under typical operating conditions as well as its performance.  Despite these 
advances however, there is very little information in the literature on possible 







The overall objective of this research work was to determine how the performance of a 
standard USP Dissolution Testing Apparatus 2 can be improved by introducing simple 
modifications to its geometry.  This goal was achieved here by assembling a slightly 
modified USP Dissolution Testing Apparatus 2 in which the impeller was placed off-
center by 8 mm, and then by determining the dissolution profiles of disintegrating 
calibrator tablets of Prednisone in both the Standard USP Dissolution Testing Apparatus 
2 and the Modified USP Dissolution Testing Apparatus 2.   
More specifically this study had a total of four specific objectives designed to 
compare the performance of these two systems, as follows: 
Objective 1:  Determination of the dissolution profiles of Prednisone tablets obtained in 
the Standard Dissolution USP Testing Apparatus 2 (Standard System) at 50 rpm 
for three different tablet locations on the vessel bottom (0°, 10° and 20° from the 
vertical vessel centerline) in order to verify that these profiles are affected by 
tablet location, as previously reported (Bai and Armenante, 2009); 
Objective 2:  Determination of the dissolution profiles of Prednisone tablets obtained in 
the Modified Dissolution USP Testing Apparatus 2 (Modified System) at 50 rpm 
for nine different nine tablet locations on the vessel bottom (one at 0°, and four 
each at 10° and 20° from the vertical vessel centerline, because of the non-
symmetry of the Modified System). 
Objective 3: Determination of the impeller agitation speed in the Modified System 





to that also for a centrally located tablet but in the Standard System rotating at 50 
rpm. 
Objective 4: Determination of the dissolution profiles of Prednisone tablets obtained in 
the Modified Dissolution USP Testing Apparatus 2 (Modified System) rotating at 
the optimum impeller rotation speed for nine different nine tablet locations on the 
vessel bottom (one at 0°, and four each at 10° and 20° from the vertical vessel 
centerline, because of the non-symmetry of the Modified System). 
 
Throughout this work, the results were interpreted by potting C/C* (drug release) against 
time (min) and by calculating the FDA recommended similarity factor (f1) and difference 
factor (f2) described below. 
Table 2.1 lists the cases (i.e., different experiments done on USP Dissolution 
Testing Apparatus 2) that were studied in this research work.  
 
Table 2.1 Different Operating Conditions of USP 2 Vessel Studied in This Work 
 






in Standard System 
50 500 Standard (i.e., centrally located 
and 25 mm off the vessel 
bottom) 
Dissolution Testing 
in Modified System 
50 500 Modified (i.e., 8 mm off 
centrally located and 25 mm 
off the vessel bottom) 
Dissolution Testing 
in Modified System 
30, 33, 34, 35, 
36, 37, 40 
500 Modified (i.e., 8 mm off 
centrally located and 25 mm 
off the vessel bottom) 
Dissolution Testing 
in Modified System 
35 500 Modified (i.e., 8 mm off 
centrally located and 25 mm 







EXPERIMENTAL APPARATUS, MATERIALS, AND METHOD 
 
3.1 Dissolution Vessel and Agitation System 
Two USP Dissolution Testing Apparatus 2 systems were used in this work, i.e., a 
Standard System and a Modified System.  The Standard System consisted of a Distek 
5100 Bathless Dissolution Apparatus shown in Figure 3.1a. (Distek Inc., North 
Brunswick, NJ) capable of operating seven dissolution vessels at a time.  An Apparatus 2 
vessel consisting of an unbaffled, cylindrical, transparent, glass tank with hemispherical 
bottom, and internal diameter, T, of 100.16 mm and overall capacity of 1 L was used as 
the dissolution vessel (Figure 3.1b).  The agitation system consisted of a standard USP 2 
two-blade paddle impeller mounted on a shaft and connected to the motor in the Distek 
system. The exact geometry of each component of the impeller was obtained by 
measuring the actual dimensions with a caliper, which were found to be as follows: shaft 
diameter, 9.53 mm; length of the top edge of the blade, 74.10 mm; length of the bottom 
edge of the blade, 42.00 mm; height of the blade, 19.00 mm; and thickness of the blade, 
5.00 mm. The impeller clearance off the vessel bottom was 25 mm, as mandated by the 
USP (2008). When the vessel was filled with 500 mL of dissolution media, the 
corresponding liquid height, H, as measured from the bottom of the vessel, was 78.6 mm.  
Figure 3.2 shows the Standard USP Dissolution Testing Apparatus 2. 
The Modified System was identical to the Standard System except for the location 





(Figure 3.3). This was accomplished by removing, for any given vessel, one of the three 
retaining spring inserts mounted on the metal plate of the Distek dissolution equipment 
that are used to keep a vessel centered in each cavity in the plate.  This resulted in a 
sideway shift of the vessel that produced a misalignment of the vessel centerline with 
respect to the impeller centerline.  By inserting a proper spacer, the distance between 
these centerlines was made to be exactly 8 mm, thus resulting in an off-centered impeller 
with respect to the vessel.  Also for this configuration, the impeller clearance off the 
vessel bottom was 25 mm, i.e., the same as in the Standard System. Figure 3.3 shows the 
Modified USP Dissolution Testing Apparatus 2.   
 
 (a) (b) 
Figure 3.1 (a) Distek 5100 Bathless Dissolution Apparatus (b) USP Dissolution Testing 
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 3.2 Experimental Materials 
Dissolution testing experiments were conducted using disintegrating solid oral dosage 
forms, i.e., Prednisone tablets (NCDA #2), which were kindly donated by Dr. Zongming 
Gao, Food and Drug Administration (FDA), Division of Pharmaceutical Analysis, Center 
for Drug Evaluation and Research, St. Louis, MO.  Each Prednisone tablet contained 10 
mg of Prednisone. A commercial acrylic glue was used to fix the tablet at a particular 
location on the bottom of the dissolution vessel. 
The dissolution medium consisted of de-aerated distilled water.  The medium was 
de-aerated according to the degassing method developed by Moore (Moore, 1996) 
following the USP General Test Chapter on DISSOLUTION <711> (Figure 3.4).  
Accordingly, the medium was placed in carboy tank, which was then connected to a 
vacuum pump.  Vacuum was applied for 30 minutes while all other valves in the system 
were closed.  This stock solution was used as needed (typically in 500 mL aliquots per 
experiment). 
A disposable PVDF 0.45 m filter was used to remove possible solid particles 







Figure 3.4 Equipment used to de-aerated the dissolution medium. 
3.3 Experimental Method 
The experimental procedure used in this work was slightly different from that typically 
used in dissolution testing (USP, 2008) since the tablet was not dropped in the stirred 
dissolution medium but was glued in place prior to the addition of the dissolution 
medium and the beginning of the experiment. 
Before each experiment, all key geometrical measurements were checked 
(impeller clearance, impeller position, etc.). When needed, the dissolution apparatus was 
modified by shifting the impeller 8 mm off center. In order to test the effect of tablet 
position during dissolution testing, a tablet was attached at a predefined spot on the vessel 
bottom with a very small bead of commercial glue. Nine positions on the vessel bottom 
were selected in the non-symmetrical Modified System, as shown in Figure 3.5 (a).  
Position 1 in this figure represents the center of the vessel bottom.  Positions 2-5 were all 
10° off-center from the vessel vertical centerline (Figure 3.5(b)).  This angle originated 
from the center of the sphere comprising the hemispherical vessel bottom, and was 





would be zero for the central point below the impeller).  Positions 2-5 were all on the 
same inner circle, and were spaced 90° apart from each other.  Positions 6-9 were 20° 
off-center from the vessel vertical centerline (Figure 3.5(b)).  The vertical centerline 
through the impeller intersected the vessel bottom between Position 1 and Position 3, 
some bottom 8 mm away from the vessel bottom. 
As for the Standard System, only three tablet positions were studied, i.e., 
Positions 1, 2 and 6, since the vessel centerline and the impeller centerline coincided, 
implying that the system was symmetrical and that Positions 3-5 were identical to 
Position 2, and Positions 7-9 were identical to Position 6.  Additional details of the 
operating conditions are presented in Table 3.1.   
Table 3.1 Operating Conditions for Dissolution Experiments with Prednisone 
Prednisone Tablet Operating Conditions 
Dose 10 mg 




Agitation Speed 50 rpm 
Filter PVDF 0.45um 
UV Wavelength (UV Spectroscopy) 242nm 
Standard Tablets Calibrated Tablets 












Figure 3.5 (a)Top View of the Bottom of the Dissolution Vessel with Nine different 
Tablet Positions in Modified System (b) The Front View of the Dissolution Vessel with 




Once the tablet and the vessel were setup properly, 500 mL of the de-aerated 
dissolution medium, previously preheated at 37.5 
o
C, was gently poured into the vessel in 
order to minimize the introduction of gas and prevent the rapid initial dissolution of the 
tablet.  Because of the thermal inertia of the vessel, the resulting temperature of the liquid 
was 37 
o
C.  This temperature was maintained throughout the dissolution experiment by 
the system‟s temperature controller.  The agitation was started immediately after the 
addition of dissolution medium. The agitation speed was always 50 rpm. The first sample 
was taken immediately after starting agitation. This data was defined as zero-time point. 
The time interval between samples was 5 minutes. Each experiment lasted 45 minutes 
and a total of 10 samples were taken for each experiment.  Experiments were performed 
in six replicates for each tablet location in the Modified System and in triplicates in the 
Standard System.  
Sampling consisted of removing a 10-mL medium aliquot with a 10-mL syringe 
connected to a cannula (2 mm ID). The volume of medium removed by sampling was not 
replaced, in accordance to the USP procedure (2008).  The sampling point was 
horizontally located midway between the impeller shaft and the vessel wall, and midway 
between the top edge of the impeller and the surface of the dissolution medium, i.e., 
within the sampling zone prescribed by the USP.  After sample withdrawal, about 2-mL 
of the sample were discarded, the cannula was removed, and a PVDF 0.45 m filter was 
mounted on the syringe. The remaining sample volume (about 8-mL) was transferred to a 
vial until analyzed.  
Analysis of samples was carried out using and 1-cm quartz cells placed in a UV-




wavelength, i.e., 242 nm for Prednisone (the approximate wavelength of maximum 
absorbance). Before putting the quartz cell into the UV spectrometer, the cell was rinsed 
three times with the same solution sample. Knowing the calibration curve described 
below, this absorption reading was used to obtain the concentration of dissolved 
Prednisone in the sample.   
A calibration curve for Prednisone was obtained. Reference standard solutions of 
the drug were prepared in the dissolution medium and diluted to obtain solutions of 
different known concentrations.  The absorbance of these solutions was obtained in order 
to generate an absorbance-vs.-concentration standard curve. These results are presented 
in Table 3.2 and Figure 3.6.  These results show that the calibration curve was linear 
(R
2
=0.9974) in the concentration range of interest here. 











Average  Absorbance 




0.156 0.155 0.155 0.155333333 0.0033 
0.241 0.242 0.241 0.241333333 0.005 
0.469 0.468 0.467 0.468 0.01 
0.564 0.565 0.563 0.564 0.0125 
0.73 0.729 0.728 0.729 0.0166 
1.012 1.011 1.009 1.010666667 0.025 






     Figure 3.6 Calibration Curve for Prednisone. 
 
3.4 Data Processing 
The dissolution profiles obtained with tablets at off-center locations in the Modified 
System were compared to those obtained with the centrally located tablets in the same 
Modified System in order to determine whether these dissolution curves were statistically 
similar or different.  Similarly, dissolution profiles obtained with tablets at off-center 
locations in the Standard System were compared to those obtained with the centrally 
located tablets in the same Standard System. 
The similarity of two dissolution profiles was determined using the FDA-
recommended approach consisting of using a model-independent method based on the 
similarity factor (f1) and difference factor (f2) proposed by Moore and Flanner (Moore 
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where Rt is the reference assay at time t, Τt is the test assay at the same time, and n is the 
number of points. The f1 factor measures the percent error between two curves for all 
points. The percent error is zero when the test and drug reference profiles are identical, 
but increases proportionally with the dissimilarity between the two dissolution profiles. 
The higher the similarity factor f1 (which can be in the range 0 to 100), the higher the 
average difference between reference and test curves is. The f2 factor is a logarithmic 
transformation of the sum-squared error of differences between the test and the reference 
products over all time points (which can be in the range -α to 100).  If this difference is 
higher than 100, normalization of the data is required.  The higher the difference factor f2, 
the lower the average difference between reference and test curves (Costa and Lobo, 
2001). Public standards have been set by Food and Drug Administration (FDA) for f1 and 
f2. Accordingly, statistical similarity between the two curves being compared requires 










As discussed above, this study had a total of four objectives to compare the performance 
of the Standard USP Dissolution Testing Apparatus 2 and the Modified USP Dissolution 
Testing Apparatus 2.  The dissolution profile of Prednisone at three different tablet 
locations (0°, 10° and 20°) in the Standard USP Dissolution Testing Apparatus 2 
(Standard System) were obtained first as per USP method.  Then the drug release profile 
of Prednisone at nine different tablet location positions was obtained for the Modified 
System as per the method described in the previous chapter. In the third series of 
experiments the optimum impeller agitation speed in the Modified system was obtained 
by changing the impeller rotation speed.  Finally, in the fourth series of experiments the 
robustness of the Modified System at an optimum agitation speed was determined. The 
results were interpreted by potting C/C* (drug release) against time (min) and by 
calculating similarity factor (f1) and difference factor (f2). 
 
4.1 Results for the Standard USP Dissolution Testing Apparatus 2 
In this section of the study, the dissolution profiles for Prednisone was obtained at three 
different tablet location (0°, 10°, 20°) at the bottom of the dissolution vessel using the 
Standard USP Dissolution System and an agitation speed of 50 rpm.  The results are 
reported here in terms of C/C*, i.e., the ratio of the Prednisone concentration in the 
dissolving medium, C, at a given time, t, relative to the final concentration, C*, obtained 





 One can easily see that there is a significant difference between all three dissolution 
profiles at three different tablet positions.  The corresponding f1 and f2 values quantifying 
the similarity/difference of the dissolution profiles with respect to that for the centrally 
located tablet are presented in the Table 4.1.  Both f1 and f2 are out of the required range 
to insure statistical similarity, which implies that tablets at the 10° and 20° locations 
would fail the dissolution test. These results confirm that the dissolution profiles of the 
chosen disintegrating solid dosage form (Prednisone) depend strongly on the tablet 
location in the dissolution vessel for the Standard System.  These results are in agreement 
with previously reported work from this and other research groups.  The results obtained 
in this study are shown in detail in Tables B.1, B.2 and B.3 in Appendix B. 
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Table 4.1 f1 and f2 values for Dissolution profiles in the Standard System at 50 rpm (grey 
areas indicate out-of-range values) 
Tablet Location   f1 (Similarity Factor)  f2 (Difference factor) 
  0°   
10° 20.168 50.193 
20° 37.951 36.853 
 
 
4.2 Results for the Modified USP Dissolution Testing Apparatus 2 
In this series of experiments, drug release profiles for Prednisone were obtained by 
placing the tablets at nine different locations in the Modified USP Dissolution Testing 
Apparatus 2. The dissolution results for the centrally located tablet and for the tablets 10° 
off center i.e., at the four locations on the inner circle, are shown in Figure 4.2a.  Figure 
4.2b shows the corresponding results for the tablets on the outer circle, if for the four 
tablet locations 20° off center.  Figure 4.3 presents the combined results.  These figures 
show the average non-dimensional concentrations (C/C*) at each time from the six 
replicate experiments at each location.  The standard deviation was typically found to be 
lower than 1% of the average value of the 6 replicates at any given time, and it was not 
reported in these figures since it was too small to be adequately displayed in the graphs.  
This small number indicates that the experiments were highly reproducible.  The actual 
dissolution data (including the standard deviations) are provided in Appendix B (Tables 
B.4-B.12).  In addition, Figures A.1 and A.2 in Appendix A show the specific drug 
release profiles for Prednisone at the four inner positions (Position 2, 3, 4 and 5), i.e., 





(Positions 6, 7, 8 and 9), i.e., those on the outer circle (20° away from the center), as 
described in Figure 3.5.   
The curves in Figure 4.3 shows that the dissolution profiles for all nine positions 
are visually overlapping on each other. This implies that there is a significant similarity 
between all nine dissolutions profiles at nine different positions. To confirm this visual 
observation, the similarity factors (f1) and difference factors (f2) were calculated for each 
of the experimental dissolution profiles for each off-center tablet with respect to the 
dissolution profile for the centrally located tablet.  The results are reported in Table 4.2.  
In all cases, the f1 factor was between 0 to15 and the f2 factor was between 50 and 100, 
indicating that the dissolution profiles for the off-center tablets were statistically similar 
to that for the centrally located tablet, according to the FDA criteria. 
From the data in this table, one can see that the tablets on the inner circle 
produced, on average, dissolution profiles that were slightly less similar to that for the 
central table than those on the outer circle.  In addition, tablet locations that were farther 
away from the impeller centerline (Positions 2 and 6), resulted in curves with slightly 
higher values for f1 and smaller values for f2, implying slightly reduced similarity 











Figure 4.2 Dissolution profiles of Prednisone at different positions in the Modified 







































Table 4.2 f1 and f2 values of the dissolution curves for tablets at different off-center 
locations compared to that for the tablet in the central position (Position 1) for the 
Modified System at 50 rpm 
Tablet Location f1 (Similarity factor) f2 (Difference factor) 
Position 1 (centered tablet)   
Position 2 (10° off-center tablet) 5.074 63.050 
Position 3 (10° off-center tablet) 4.174 72.520 
Position 4 (10° off-center tablet) 3.299 78.517 
Position 5 (10° off-center tablet) 3.011 74.353 
Position 6 (20° off-center tablet) 3.758 66.326 
Position 7 (20° off-center tablet) 3.279 74.640 
Position 8 (20° off-center tablet) 3.070 71.002 




Figure 4.3 Dissolution profiles of Prednisone at nine different positions in the Modified 

























4.3 Determination of the Optimum Impeller Rotation Speed in the Modified System 
Resulting in a Dissolution Profile Similar to That in the Standard System for a 
Centrally Placed Tablet 
In this portion of the work, the dissolution profile for a centrally located tablet in the 
Standard System operating at 50 rpm was compared with the dissolution profiles in the 
Modified System obtained at different agitation speeds in order to determine for what 
speed in the latter system the two profiles in the Standard and Modified Systems were 
similar. 
Initial experiments were conducted in both systems at the same agitation speed, 
i.e., 50 rpm.  The results, reported in Figure 4.4, clearly show that dissolution in the 
Modified System was appreciably faster than in the Standard System.  This is to be 
expected, since the non-symmetrical, off-center location of the impeller produces a 
“baffling effect” in the vessel similar (but not identical) to that observed in a stirred tank 
provided with a vertical baffle.  Baffles are routinely inserted in mixing vessels to prevent 
swirling and vortex formation, reduce the tangential component of the fluid velocity 
while increasing the vertical component, thus improving fluid mixing.  Such improved 
mixing can be observed in Figure 4.4 for the Modified System. 
However, the objective of dissolution testing is not to conduct efficient mixing 
operations, but to simulate dissolution in the gastrointestinal tract.  Therefore, an 
additional objective of this work was to determine for which agitation speed the Modified 
System behaved similarly to the Standard System, at least for the case of a centrally 
located tablet.  Therefore, additional dissolution experiments were conducted at different 
agitation speeds in the Modified System in order to mimic the behavior of the Standard 




System at different speeds (i.e., 30 rpm, 33 rpm, 34 rpm, 35 rpm, 36 rpm, 37 rpm and 40 
rpm), until the appropriate speed was determined.  Table 4.3 gives the f1 and f2 values 
obtained when the profiles in the Modified System were compared with that for the 
Standard System at 50 rpm.  From this table, it can be concluded that the Modified 
System produces results similar to the Standard System when operated at an agitation 
speed between 34 and 35 rpm.  It was decided to choose 35 rpm as the Modified 
System‟s “equivalent agitation speed” for the Standard System operating at 50 rpm.  At 
this speed the Modified System produces dissolution profiles that are statistically similar 
to those in the Standard System (f1=2.578; f2=88.120).  Additional details for these 
experiments are shown in Tables B.13-B.19 in Appendix B. 
 
Figure 4.4 Comparison of dissolution profiles for a centrally located tablet in the 
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Figure 4.5 Dissolution profiles for a centrally located tablet in the Standard System at 50 




Figure 4.6 Comparison of dissolution profiles for a centrally located tablet in the 





































Table 4.3 f1 and f2 values for the dissolution profiles at different agitation speeds in the 
Modified System with respect to the Standard System operated at 50 rpm 
Agitation Speed (rpm) f1 (Similarity factor) f2 (Difference factor) 
30 40.632 35.066 
33 11.341 62.128 
34 2.386 84.713 
35 2.578 88.120 
36 15.665 55.613 
37 16.093 55.108 
40 16.507 53.931 
 
4.4 Dissolution in the Modified System at the Optimum Agitation Speed (35 rpm) 
for This System 
The results from the previous section show that the Modified System at 35 rpm is 
equivalent to the Standard System at 50 rpm at least for the centrally located tablet.  
However, it was still unclear whether the Modified System operated at 35 rpm was still 
robust enough to be insensitive to variation in tablet location, i.e., if it still behaved 
similarly to what found for the Modified System operated at 50 rpm.  Therefore, a new 
series of experiments was conducted at 35 rpm in the Modified System in which the 
tablets were placed at each one of the nine locations mentioned previously (Figure 3.5).   
The results presented in Figure 4.7 show that that the dissolution profiles for the 
Modified system at 35 rpm at all nine positions are visually overlapping on each other. 
This implies that there is a significant similarity between the dissolutions profiles at all 
nine different positions, even at 35 rpm. To confirm this observation, the similarity 
factors (f1) and difference factors (f2) were calculated for each of the experimental 
dissolution profiles for each off-center tablet with respect to the dissolution profile for the 




factor was between 0 and 15 and the f2 factor was between 50 and 100, indicating that the 
dissolution profiles for the off-center tablets were statistically similar to that for the 
centrally located tablet, according to the FDA criteria.  Additional details are provided in 
Tables B.20-B.27 in Appendix B. 
 
Figure 4.7 Dissolution profile for Prednisone at nine different tablet positions in the 
Modified System at 35 rpm. 
 
Table 4.4 f1 and f2 values of the dissolution curves for tablets at different off-center 
locations compared to that for the tablet in the central position (Position 1) for the 
Modified System at 35 rpm 
Tablet Location f1 (Similarity factor) f2 (Difference factor) 
Position 1 (centered tablet) 2.933 86.388 
Position 2 (10° off-center tablet) 2.276 89.727 
Position 3 (10° off-center tablet) 3.337 84.481 
Position 4 (10° off-center tablet) 5.761 75.669 
Position 5 (10° off-center tablet) 2.919 83.456 
Position 6 (20° off-center tablet) 2.530 91.600 
Position 7 (20° off-center tablet) 4.836 77.859 
Position 8 (20° off-center tablet) 5.957 73.253 



























The results of this work confirm that the location of the tablet on the vessel bottom has a 
significant impact on the dissolution profiles in the Standard USP Apparatus 2, where the 
impeller is centrally located in the vessel.  When the tablet is located in a central position 
at the bottom of the vessel, the dissolution process at 50 rpm and with 500 mL of 
dissolving medium is slower than when the tablet is at other locations, such as 10° and 
20° from the vertical centerline.  This is consistent with the results of other investigators, 
and with the hydrodynamics of this system.  In fact, in the region just below the impeller 
the flow is in general weak and the dissolution rate slow in comparison with the flow just 
outside this region, i.e., where the 10° and 20° off-center tablets are located.  This is 
further confirmed by the values of the f1 and f2 parameters for these cases. 
By contrast, when the Modified USP Dissolution Testing Apparatus 2 is used, the 
dissolution profiles obtained with tablet at different locations appear to be much more 
similar to each other and to the dissolution profile for the centrally located tablet.  The 
reason for this can be attributed to the non-symmetric position of the impeller, which is 
likely to produce a sweeping flow along the vessel bottom, thus avoiding the formation of 
a nearly stagnant zone near the center of the vessel bottom, as in the Standard System, 
and making the tablets dissolve at similar rates irrespective of their position.  This 
behavior is again confirmed by the appropriate values for the f1 and f2 parameters. 
As a result of its non-symmetrical location of the impeller, the Modified System is 





dissolution profiles with the two systems when the tablet is in the same central location 
shows that the dissolution process in the former system is faster than that in the latter 
system at the same agitation speed.  Since the operators or dissolution testing laboratories 
are familiar with the Standard Systems and expect the process to proceed at this slower 
rate, it was considered necessary here to determine the agitation intensity in the Modified 
System that produced a dissolution profile similar to the Standard System for the 
“normal” case in which the tablet is centrally located.  This agitation speed was found to 
be in the range 34-35 rpm, implying that a Modified System operated at this speed 
produces a dissolution curve very similar to that obtained at 50 rpm with the Standard 
System. 
In order to determine whether operating the Modified System at this speed would 
still results in dissolution curves insensitive to tablet location, a new series of experiments 
were conducted with the tablets placed at different locations.  The results showed that the 
Modified System is still insensitive to tablet location as evidenced by the appropriate 
values of the f1 and f2 parameters. 
Therefore, it can be concluded that the Modified System when operated at 35 rpm 
instead of 50 rpm generates not only dissolution rates and dissolution profiles that are 
similar to those obtained in current systems, but it is additionally much more robust in 
terms of reproducibility and insensitivities to parameter that can instead significantly 
affect the results of the Standard System. 
Modifying a Standard System is very simple, and a number of ways to do so have 





the newly proposed Modified System for dissolution testing could be a valid alternative 








A number of conclusions can be drawn from this work, as follows: 
1. The dissolution performance of Prednisone tablets, as disintegrating oral dosage 
forms, in the Standard Dissolution System where the impeller is placed centrally and 
symmetrically with respect to the unbaffled hemispherical-bottom vessel of the USP 
Dissolution Testing Apparatus 2 is strongly dependent on tablet position, as 
previously reported by this and other research groups.  Thus, this apparatus is prone 
to highly variable results which may not be associated with the tablets undergoing 
testing but with hydrodynamic characteristics of the apparatus itself and the location 
of the tablet on the vessel bottom. 
 
A modification of the USP Dissolution Testing Apparatus 2 in which the impeller 
was placed off-center by 8 mm was proposed, and a prototype was assembled, and 
tested in this work.  This Modified System generated dissolution profiles for 
Prednisone tablets that were nearly completely insensitive to tablet location. 
 
2. The dissolution profiles for Prednisone in the Modified System were steeper than in 
the Standard System because of the improved mixing performance of the Modified 
System resulting from the non-symmetrical placement of the impeller. 
 
3. When the Modified System was operated at 35 rpm, the dissolution profiles for 
centrally located tablets were very similar to those for the Standard System at 50 
rpm. 
 
4. The dissolution profiles for Prednisone tablets at 35 rpm in the Modified System 
were found to be insensitive to tablet location.   
 
5. The newly proposed Modified System for dissolution testing could be a simple and 
valid alternative to the current dissolution testing practice using the Standard USP 










FIGURES FOR CHAPTER 4 
 
Appendix A includes figures of Chapter 4. It includes Dissolution profiles of Prednisone 









Figure A.1 Dissolution profile of Prednisone in Modified System at different positions 


























Figure A.2 Dissolution profile of Prednisone in Modified System at different positions 





















TABLES FOR CHAPTER 4 
 
This appendix includes all tables of Chapter 4. Dissolution profiles of Prednisone in both 
Standard (Tables B.1-B.3) and in Modified (Tables B.4-B.12) Systems are represented in 
detail in this appendix. Dissolution profiles of prednisone in Modified system at 0° 
position at different impeller rotation speed (Tables B.13-B.19) are presented in this 
appendix. It also includes the Dissolution profile of prednisone in Modified system at 35 

































0 0.074 0.0233 -0.0003 0.0014242 0.07121 0.000577 
5 0.185 0.0233 -0.0003 0.0040105 0.200525 0.001 
10 0.298 0.0233 -0.0003 0.0066434 0.33217 0.001155 
15 0.381 0.0233 -0.0003 0.0085773 0.428865 0.000577 
20 0.424 0.0233 -0.0003 0.0095792 0.47896 0.001 
25 0.477 0.0233 -0.0003 0.0108141 0.540705 0.000577 
30 0.517 0.0233 -0.0003 0.0117461 0.587305 0.000577 
35 0.551 0.0233 -0.0003 0.0125383 0.626915 0.000577 
40 0.575 0.0233 -0.0003 0.0130975 0.654875 0.001 
45 0.605 0.0233 -0.0003 0.0137965 0.689825 0.000577 
 
 





















    C/C* 
   
  f1 
   
 f2 
0 0.095 0.0233 -0.0003 0.0019135 0.0956 0.0005774 
 
20.16 50.19 
5 0.238 0.0233 -0.0003 0.0052454 0.2622 0.0005774 
 
  
10 0.359 0.0233 -0.0003 0.0080647 0.4032 0.0005774 
 
  
15 0.475 0.0233 -0.0003 0.0107675 0.5383 0.0005774 
 
  
20 0.535 0.0233 -0.0003 0.0121655 0.6082 0.0005774 
 
  
25 0.581 0.0233 -0.0003 0.0132373 0.6618 0.0005774 
 
  
30 0.607 0.0233 -0.0003 0.0138431 0.6921 0.0005774 
 
  
35 0.645 0.0233 -0.0003 0.0147285 0.7364 0.0005774 
 
  
40 0.674 0.0233 -0.0003 0.0154042 0.7702 0.0005774 
 
  

























   
Standard 
Deviation 
  C/C* 
   
f1 
   
  f2 
0 0.125 0.0233 -0.0003 0.0026125 0.13062 0.0005774 
 
37.95 36.85 
5 0.31 0.0233 -0.0003 0.006923 0.34615 0.0057735 
 
  
10 0.461 0.0233 -0.0003 0.0104413 0.52206 0.0005774 
 
  
5 0.557 0.0233 -0.0003 0.0126781 0.63390 0.0005774 
 
  
20 0.613 0.0233 -0.0003 0.0139829 0.69914 0.0005774 
 
  
25 0.657 0.0233 -0.0003 0.0150081 0.75040 0.0051962 
 
  
30 0.698 0.0233 -0.0003 0.0159634 0.79817 0.0005774 
 
  
35 0.714 0.0233 -0.0003 0.0163362 0.81681 0.0005774 
 
  
40 0.739 0.0233 -0.0003 0.0169187 0.84593 0.0005774 
 
  




























0 0.029 0.0233 -0.0003 0.00037958 0.0189 .00009512 
5 0.284 0.0233 -0.0003 0.006323 0.3160 0.00018935 
 
10 0.511 0.0233 -0.0003 0.011615 0.5807 0.000190244 
 
15 0.631 0.0233 -0.0003 0.014410 0.7205 0.000366559 
 
20 0.702 0.0233 -0.0003 0.016076 0.8038 0.000120321 
 
25 0.744 0.0233 -0.0003 0.017040 0.8520 0.000141089 
 
30 0.772 0.0233 -0.0003 0.017704 0.8852 0.000120321 
 
35 0.786 0.0233 -0.0003 0.018020 0.9010 0.000104201 
 
40 0.808 0.0233 -0.0003 0.01854 0.9274 0.000475609 
 




















   











0 0.109 0.0233 -0.0003 0.00225 0.11256 0.000337649 
 
5.07 63.04 
5 0.404 0.0233 -0.0003 0.00912 0.45608 0.00440035 
 
  
10 0.577 0.0233 -0.0003 0.01314 0.65732 0.003295461 
 
  
15 0.672 0.0233 -0.0003 0.01529 0.76496 0.00539455 
 
  
20 0.723 0.0233 -0.0003 0.01656 0.82818 0.002342104 
 
  
25 0.760 0.0233 -0.0003 0.01741 0.87098 0.001020068 
 
  
30 0.784 0.0233 -0.0003 0.01797 0.89894 0.001189023 
 
  
35 0.802 0.0233 -0.0003 0.01839 0.91971 0.001221862 
 
  
40 0.820 0.0233 -0.0003 0.01880 0.9403 0.001605842 
 
  





























0 0.0855 0.0233 -0.0003 0.00169 0.08460 0.000141089 
 
4.17 72.52 
5 0.347567 0.0233 -0.0003 0.00779 0.38991 0.0000951 
 
  
10 0.5276 0.0233 -0.0003 0.0119 0.59964 0.053162615 
 
  
15 0.664 0.0233 -0.0003 0.01517 0.75856 0.001591693 
 
  
20 0.7289 0.0233 -0.0003 0.01668 0.83416 0.00070448 
 
  
25 0.7681 0.0233 -0.0003 0.01759 0.87983 0.001424448 
 
  
30 0.788267 0.0233 -0.0003 0.01806 0.90373 0.000975869 
 
  
35 0.8153 0.0233 -0.0003 0.01869 0.93482 0.001001268 
 
  
40 0.83225 0.0233 -0.0003 0.01907 0.95459 0.00104396 
 
  

































0 0.095 0.0233 -0.0003 0.00191583 0.097386 0.004377931 
 
3.29 78.51 
5 0.299 0.0233 -0.0003 0.0066667 0.33253 0.011311104 
 
  
10 0.495 0.0233 -0.0003 0.011249033 0.56245 0.003944977 
 
  
15 0.608 0.0233 -0.0003 0.013885817 0.69429 0.005592202 
 
  
20 0.671 0.0233 -0.0003 0.01534595 0.76729 0.007408673 
 
  
25 0.727 0.0233 -0.0003 0.016658517 0.83292 0.003691721 
 
  
30 0.744 0.0233 -0.0003 0.0170352 0.85176 0.00399625 
 
  
35 0.769 0.0233 -0.0003 0.01762935 0.8798 0.003617445 
 
  
40 0.786 0.0233 -0.0003 0.018017683 0.90088 0.004064999 
 
  






























0 0.071 0.0233 -0.0003 0.001406 0.07031 0.003213092 
 
3.01 74.35 
5 0.356 0.0233 -0.0003 0.00800 0.40030 0.003234772 
 
  
10 0.539 0.0233 -0.0003 0.01226 0.61333 0.000586756 
 
  
15 0.636 0.0233 -0.0003 0.01451 0.7264 0.000695122 
 
  
20 0.691 0.0233 -0.0003 0.01590 0.79510 0.004700839 
 
  
25 0.724 0.0233 -0.0003 0.01659 0.82967 0.002588031 
 
  
30 0.756 0.0233 -0.0003 0.01736 0.86838 0.004648141 
 
  
35 0.782 0.0233 -0.0003 0.01792 0.89613 0.00110132 
 
  
40 0.796 0.0233 -0.0003 0.01824 0.91246 0.003194452 
 
  
































0 0.108 0.0233 -0.0003 0.00225 0.11156 0.001054952 
 
3.75 66.32 
5 0.395 0.0233 -0.0003 0.0089 0.44614 0.002489577 
 
  
10 0.566 0.0233 -0.0003 0.012748 0.6374 0.007477812 
 
  
15 0.652 0.0233 -0.0003 0.01490 0.74535 0.029953568 
 
  
20 0.714 0.0233 -0.0003 0.01635 0.81758 0.004522041 
 
  
25 0.747 0.0233 -0.0003 0.01711 0.8556 0.002290838 
 
  
30 0.776 0.0233 -0.0003 0.01778 0.88905 0.002210944 
 
  
35 0.798 0.0233 -0.0003 0.01830 0.91544 0.000951219 
 
  
40 0.815 0.0233 -0.0003 0.01870 0.93505 0.000974709 
 
  






























0 0.082 0.0233 -0.0003 0.001658753 0.0829 0.00265729 
 
3.13 74.80 
5 0.352 0.0233 -0.0003 0.007902377 0.3951 0.001433786 
 
  
10 0.521 0.0233 -0.0003 0.01184396 0.5921 0.001061152 
 
  
15 0.621 0.0233 -0.0003 0.014165417 0.7082 0.002802223 
 
  
20 0.681 0.0233 -0.0003 0.015582057 0.7791 0.00057743 
 
  
25 0.725 0.0233 -0.0003 0.016593277 0.8296 0.000731882 
 
  
30 0.753 0.0233 -0.0003 0.01725927 0.8609 0.003456472 
 
  
35 0.783 0.0233 -0.0003 0.017955457 0.8932 0.003456472 
 
  
40 0.794 0.0233 -0.0003 0.018228163 0.9074 0.004949491 
 
  







Table B.11 Dissolution profile of Prednisone in Modified System at Position 8 
 


























0 0.087 0.0233 -0.0003 0.00174651 0.08732 0.001714834 
 
3.07 71.00 
5 0.370 0.0233 -0.0003 0.0083353 0.41676 0.00121257 
 
  
10 0.555 0.0233 -0.0003 0.012639 0.63196 0.002017839 
 
  
15 0.648 0.0233 -0.0003 0.0148111 0.74056 0.000672613 
 
  
20 0.711 0.0233 -0.0003 0.0162815 0.81407 0.007434428 
 
  





30 0.766 0.0233 -0.0003 0.0175478 0.87739 0.004035678 
 
  
35 0.791 0.0233 -0.0003 0.0181357 0.90678 0.000641632 
 
  
40 0.804 0.0233 -0.0003 0.01834487 0.9224 0.000672613 
 
  



























0 0.04417 0.0233 -0.0003 0.000729083 0.0364 0.004798707 
 
3.32 77.22 
5 0.2878 0.0233 -0.0003 0.0064057 0.32028 0.020559263 
 
  
10 0.50018 0.0233 -0.0003 0.01135427 0.56771 0.024343808 
 
  
15 0.61352 0.0233 -0.0003 0.0139949 0.69974 0.025359609 
 
  
20 0.6632 0.0233 -0.0003 0.0151541 0.75770 0.003732851 
 
  
25 0.7205 0.0233 -0.0003 0.016481825 0.82409 0.002839112 
 
  
30 0.74238 0.0233 -0.0003 0.016997532 0.84987 0.00487489 
 
  
35 0.76472 0.0233 -0.0003 0.017517898 0.87589 0.004135613 
 
  
40 0.77982 0.0233 -0.0003 0.017869728 0.89348 0.001189023 
 
  






























   
 f2 
0 0.061 0.0233 -0.0003 0.0011213 0.05606 0.002828 
 
40.63 35.06 
5 0.103 0.0233 -0.0003 0.0020999 0.10499 0.005657 
 
  
10 0.150 0.0233 -0.0003 0.003195 0.15975 0.002828 
 
  
15 0.197 0.0233 -0.0003 0.0042901 0.21450 0.001414 
 
  
20 0.244 0.0233 -0.0003 0.0053852 0.26926 0.004243 
 
  
25 0.286 0.0233 -0.0003 0.0063638 0.31819 0.009899 
 
  
30 0.319 0.0233 -0.0003 0.00714435 0.35721 0.013435 
 
  
35 0.353 0.0233 -0.0003 0.0079249 0.39624 0.014142 
 
  
40 0.376 0.0233 -0.0003 0.00847245 0.42362 0.016263 
 
  






























0 0.079 0.0233 -0.0003 0.00155235 0.077 0.000707 
 
11.34 62.12 
5 0.169 0.0233 -0.0003 0.0036377 0.181 0.012728 
 
  
10 0.250 0.0233 -0.0003 0.00553665 0.276 0.000707 
 
  
15 0.325 0.0233 -0.0003 0.0072725 0.363 0 
 
  
20 0.380 0.0233 -0.0003 0.008554 0.427 0 
 
  
25 0.430 0.0233 -0.0003 0.009719 0.485 0 
 
  
30 0.467 0.0233 -0.0003 0.0105811 0.529 0 
 
  
35 0.493 0.0233 -0.0003 0.0111869 0.559 0 
 
  
40 0.520 0.0233 -0.0003 0.011816 0.590 0 
 
  


































0 0.076 0.0233 -0.0003 0.0014708 0.0735 0 2.38 84.71 
5 0.157 0.0233 -0.0003 0.0033581 0.1679 0   
10 0.265 0.0233 -0.0003 0.0058745 0.2937 0   
15 0.362 0.0233 -0.0003 0.0081346 0.4067 0   
20 0.425 0.0233 -0.0003 0.0096025 0.4801 0   
25 0.479 0.0233 -0.0003 0.0108607 0.5430 0   
30 0.514 0.0233 -0.0003 0.0116762 0.5838 0   
35 0.552 0.0233 -0.0003 0.0125616 0.6280 0   
40 0.574 0.0233 -0.0003 0.0130742 0.6537 0   
45 0.610 0.0233 -0.0003 0.013913 0.6956 0   
 






















   
  f1 
  
 f2 
0 0.062 0.0233 -0.0003 0.0011563 0.05781 0.00495 
 
2.57 88.12 
5 0.171 0.0233 -0.0003 0.003696 0.18479 0.014849 
 
  
10 0.279 0.0233 -0.0003 0.0062124 0.31061 0.009192 
 
  
15 0.373 0.0233 -0.0003 0.0084026 0.42012 0.007778 
 
  
20 0.436 0.0233 -0.0003 0.0098705 0.49352 0.013435 
 
  
25 0.484 0.0233 -0.0003 0.0109772 0.54886 0.005657 
 
  
30 0.516 0.0233 -0.0003 0.0117345 0.58672 0.006364 
 
  
35 0.542 0.0233 -0.0003 0.0123286 0.61643 0.001414 
 
  
40 0.565 0.0233 -0.0003 0.0128762 0.64380 0.009192 
 
  



































0 0.088 0.0233 -0.0003 0.001762 0.088 0.000707 
 
15.66 55.61 
5 0.219 0.0233 -0.0003 0.004814 0.240 0.000707 
 
  
10 0.378 0.0233 -0.0003 0.008519 0.425 0.000707 
 
  
15 0.455 0.0233 -0.0003 0.010313 0.515 0.000707 
 
  
20 0.498 0.0233 -0.0003 0.011315 0.565 0.000707 
 
  
25 0.542 0.0233 -0.0003 0.012340 0.617 0.000707 
 
  
30 0.579 0.0233 -0.0003 0.013202 0.660 0.000707 
 
  
35 0.610 0.0233 -0.0003 0.013924 0.696 0.000707 
 
  
40 0.649 0.0233 -0.0003 0.014833 0.741 0.000707 
 
  






























0 0.083 0.0233 -0.00013 0.00181555 0.090 0.003536 
 
16.09 55.10 
5 0.217 0.0233 -0.00013 0.0049261 0.246 0.011314 
 
  
10 0.351 0.0233 -0.00013 0.0080483 0.402 0.022627 
 
  
15 0.440 0.0233 -0.00013 0.010122 0.506 0.009899 
 
  
20 0.499 0.0233 -0.00013 0.01150835 0.574 0.003536 
 
  
25 0.556 0.0233 -0.00013 0.0128248 0.641 0.008485 
 
  
30 0.589 0.0233 -0.00013 0.01360535 0.680 0.007778 
 
  
35 0.612 0.0233 -0.00013 0.01414125 0.707 0.00495 
 
  
40 0.641 0.0233 -0.00013 0.0148053 0.740 0.009899 
 
  

































0 0.074 0.0233 -0.0003 0.0014242 0.071 0 
 
16.50 53.93 
5 0.203 0.0233 -0.0003 0.0044299 0.221 3.4E-17 
 
  
10 0.350 0.0233 -0.0003 0.007855 0.392 6.8E-17 
 
  
15 0.450 0.0233 -0.0003 0.010200533 0.510 0.000577 
 
  
20 0.501 0.0233 -0.0003 0.0113733 0.568 0 
 
  
25 0.573 0.0233 -0.0003 0.0130509 0.652 0 
 
  
30 0.611 0.0233 -0.0003 0.0139363 0.696 0 
 
  
35 0.632 0.0233 -0.0003 0.014441133 0.722 0.000577 
 
  
40 0.655 0.0233 -0.0003 0.014969267 0.748 0.000577 
 
  


























    
f1 
    
f2 




















































































   
 f1 
   
 f2 










10 0.265 0.0233 -0.0003 0.0058745 0.29372 0.007071 
 
  


























35 0.547 0.0233 -0.0003 0.01296935 0.62283 0.030406 
 
  
40 0.572 0.0233 -0.0003 0.0130276 0.65138 0.001414 
 
  


























    
f1 
    
f2 
0 0.079 0.0233 -0.0003 0.0015407 0.0770 0.001414214 
 
3.33 84.48 
5 0.152 0.0233 -0.0003 0.0032416 0.1620 0.009899495 
 
  
10 0.257 0.0233 -0.0003 0.0056881 0.2844 0.004242641 
 
  
15 0.365 0.0233 -0.0003 0.00821615 0.4108 0.007778175 
 
  
20 0.436 0.0233 -0.0003 0.0098588 0.4929 0.005656854 
 
  
25 0.494 0.0233 -0.0003 0.01122185 0.5610 0.006363961 
 
  












40 0.574 0.0233 -0.0003 0.01308585 0.6542 0.00212132 
 
  





























   
 f1 
    
f2 
0 0.070 0.0233 -0.0003 0.001332165 0.0666 0.0000705 
 
5.76 75.66 
5 0.199 0.0233 -0.0003 0.00434835 0.2174 0.000707107 
 
  
10 0.297 0.0233 -0.0003 0.0066201 0.3310 0.002828427 
 
  































































C/C*   
  
  f1 





























































































  C/C* 
   
 f1 
    
f2 
0 0.082 0.0233 -0.0003 0.00162225 0.0811 0.00212132 
 
2.53 9.60 
5 0.165 0.0233 -0.0003 0.0035445 0.1772 0.035355339 
 
  
10 0.274 0.0233 -0.0003 0.00609585 0.3047 0.030405592 
 
  












25 0.494 0.0233 -0.0003 0.01122185 0.5610 0.006363961 
 
  
30 0.529 0.0233 -0.0003 0.0120257 0.6012 0.002828427 
 
  
35 0.551 0.0233 -0.0003 0.01254995 0.6274 0.004949747 
 
  
40 0.580 0.0233 -0.0003 0.013214 0.6607 0.001414214 
 
  

























    
f1 











5 0.177 0.0233 -0.0003 0.0038241 0.191205 0.002828427 
 
  
10 0.299 0.0233 -0.0003 0.0066667 0.333335 0 
 
  
15 0.389 0.0233 -0.0003 0.00877535 0.438767 0.000707107 
 
  





0.0233 -0.0003 0.01150145 0.575072 0.00212132 
 
  
30 0.552 0.0233 -0.0003 0.0125616 0.62808 0.002828427 
 
  













































    
f1 
    
f2 
0 0.079 0.0233 -0.0003 0.001562835 0.078141 7.07107E-05 
 
5.95 73.25 
5 0.199 0.0233 -0.0003 0.00434835 0.217417 0.000707107 
 
  
10 0.288 0.0233 -0.0003 0.0064104 0.32052 0.001414214 
 
  
15 0.377 0.0233 -0.0003 0.0084841 0.424205 0.002828427 
 
  
20 0.461 0.0233 -0.0003 0.0104413 0.522065 0 
 
  
25 0.533 0.0233 -0.0003 0.01213055 0.606527 0.00212132 
 
  
30 0.560 0.0233 -0.0003 0.01275965 0.637982 0.003535534 
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